H.C. Wainwright lowered the firm’s price target on Co-Diagnostics (CODX) to $1 from $1.50 and keeps a Neutral rating on the shares following the Q4 report. The firm cites the company’s higher number of shares outstanding and lower cash position for the target cut.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CODX:
- Co-Diagnostics Reports 2024 Financial Results and Strategic Progress
- Options Volatility and Implied Earnings Moves Today, March 27, 2025
- CODX Earnings this Week: How Will it Perform?
- Options Volatility and Implied Earnings Moves This Week, March 24 – March 27, 2025
- Co-Diagnostics wins dismissal of class action lawsuit
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue